[Secondary acute myeloid leukemia complicated after treatment of non-Hodgkin's lymphoma].
The aim of this study was to investigate the mechanism, susceptibility, (18)F-FDG positron emission computerized tomography ((18)F-FDG PET/CT) features and the treatment of therapy-related acute myeloid leukemia. One patient with NHL was affected with t-MDS after treatment and then progressed to t-AML. The clinical data including bone marrow cell morphology, flow cytometry, karyotype and PET/CT features were analyzed. The results showed that the primary treatment for NHL refers to varieties of cytotoxic drug such as cyclophosphamide-hydroxydaunomycin-oncovin-prednisone (CHOP) chemotherapy. The interval time from the chemotherapy of NHL to the occurrence of t-MDS was 105 months and t-MDS progressed to AML-M(2) in 2 months. Karyotype analysis results of t-MDS and t-AML were normal. (18)F-FDG PET indicated that the FDG uptake in the bone raised diffusely. The patient showed complete response after second-line therapy (CAG regiments). In conclusion, the occurrence of t-AML/MDS may be associated with the application of the cytotoxic chemotherapeutics. (18)F-FDG PET may be an indicator predicting the transformation of t-MDS to t-AML.
Liu
Yi-Qian
YQ
Biotherapeutic Center of Tumors, The First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, Jiangsu Province, China.
Qiu
Hong-Xia
HX
Li
Jian-Yong
JY
Xu
Wei
W
Xu
Ji
J
Lü
Xin
X
Wu
Han-Xin
HX
D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000209:etiology*; D008228:Lymphoma, Non-Hodgkin / Q000150:complications* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000209:etiology*; D049268:Positron-Emission Tomography